Jaguar Animal Health to Hold Special Meeting of Stockholders July 27, 2017 to Vote Upon the Consummation of its Proposed Merger with Napo Pharmaceuticals, Inc.
Terms of Proposed Merger Include Funding for Combined Company and Other Aspects of the Merger Disclosed in the Proxy/Prospectus
Jaguar to Host Conference Call
In connection with the proposed merger, Jaguar has filed with the
The special meeting of Jaguar stockholders will be held at Jaguar’s
Jaguar’s board of directors unanimously recommends that Jaguar stockholders vote “FOR” all of the proposals described in the joint proxy statement/prospectus.
Upon the consummation of the merger, Jaguar’s name will be changed to
The Jaguar management team will host a call on
For interested individuals unable to join the conference call, a replay
of the webcast will be available on the investor relations section of
Jaguar’s website (click
here) for 90 days following the call. Also, a dial-in replay of the
call will be available through
Important Additional Information will be Filed with the
Jaguar and certain of its directors and executive officers may be deemed
to be participants in the solicitation of proxies in connection with the
potential merger. Information about the executive officers and directors
of Jaguar is set forth in Jaguar’s Annual Report on Form 10-K/A for the
fiscal year ended
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities or a solicitation of any
vote or approval nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of any
such jurisdiction. Jaguar has filed a registration statement on Form
S-4, including a joint proxy statement/prospectus of Jaguar and Napo,
and other materials with the
Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com.
Crofelemer, the active ingredient in Mytesi®, is a botanical
(plant-based) drug extracted and purified from the red bark sap of the
medicinal Croton lechleri tree in the
For more information, please visit www.napopharma.com.
For more information about Jaguar, please visit www.jaguaranimalhealth.com.
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding the proposed merger between Jaguar and Napo, Jaguar’s intention to develop species-specific formulations of Neonorm™ in additional target species, and Jaguar’s plan to develop formulations of Canalevia™ for cats, horses and dogs. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
KCSA Strategic Communications
Garth Russell, 212-896-1250